L

Lavipharm SA
ATHEX:LAVI

Watchlist Manager
Lavipharm SA
ATHEX:LAVI
Watchlist
Price: 0.985 EUR 1.55% Market Closed
Market Cap: 166.2m EUR

Relative Value

The Relative Value of one LAVI stock under the Base Case scenario is hidden EUR. Compared to the current market price of 0.985 EUR, Lavipharm SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAVI Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
54
Median 3Y
2.5
Median 5Y
1.7
Industry
2.6
vs History
28
vs Industry
32
Median 3Y
42.3
Median 5Y
16.3
Industry
21.4
vs History
9
vs Industry
7
Median 3Y
50.8
Median 5Y
28.9
Industry
16.4
vs History
vs Industry
Median 3Y
-13.2
Median 5Y
-18.9
Industry
22.8
vs History
11
vs Industry
27
Median 3Y
2.6
Median 5Y
2.3
Industry
2.2
vs History
0
vs Industry
50
Median 3Y
2.9
Median 5Y
1.8
Industry
2.9
vs History
3
vs Industry
44
Median 3Y
6.2
Median 5Y
4.3
Industry
5.5
vs History
14
vs Industry
29
Median 3Y
14.9
Median 5Y
11.4
Industry
13
vs History
11
vs Industry
23
Median 3Y
26
Median 5Y
16.3
Industry
16.5
vs History
9
vs Industry
6
Median 3Y
57.7
Median 5Y
33.5
Industry
15.6
vs History
vs Industry
Median 3Y
-29
Median 5Y
-3.5
Industry
18.7
vs History
9
vs Industry
37
Median 3Y
1.7
Median 5Y
1.7
Industry
1.9

Multiples Across Competitors

LAVI Competitors Multiples
Lavipharm SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
GR
Lavipharm SA
ATHEX:LAVI
166.2m EUR 3.1 43 16.8 30.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.3 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
GR
L
Lavipharm SA
ATHEX:LAVI
Average P/E: 26.4
43
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
GR
L
Lavipharm SA
ATHEX:LAVI
Average EV/EBITDA: 401.3
16.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
GR
L
Lavipharm SA
ATHEX:LAVI
Average EV/EBIT: 1 714.9
30.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5